In Malaysia, ovarian cancer is the 4th most common cancer among women, frequently diagnosed in an advanced stage and with an aggressive clinical course. Despite surgical resection and standard chemotherapy, 70% of the patients may experience disease relapse within 3 years. The introduction of poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitors (PARPi) has marked a crucial step forward in the treatment of these patients. Therefore, the evaluation of BRCA1 and BRCA2 status is encouraged for all patients with advanced non-mucinous epithelial ovarian cancer to guide the therapy decision.BRCA Mutations accounts for about 22-30% of High grade serous ovarian carcinoma patients, and with the advent of targeted therapy, identifying patients harboring these mutations plays a pivotal role in treatment decision besides assessing family risk. In this course, expert leading consultant pathologist, Prof Pathmanathan will detail on the Who, Why When What & How of BRCA testing as well as deep diving in the science of BRCA genes in Ovarian Cancer.AstraZeneca is leading this digital initiative to focus on educating the gynaecologists on ovarian cancer.Learning ObjectivesThe initiative is based on the theme of "Transforming Ovarian Cancer Care Together" and aims to:
- Increase the awareness of ovarian cancer among HCPs, (especially gynaecologists who are treating ovarian cancer) in order to improve early detection for timely management of ovarian cancer.
- Improve the outcome of ovarian cancer management-to increase the chances of a curative intent of the disease and delay progression for as long as possible.
- Call to action: Gynaecologists are able to discuss BRCA testing with their patients and refer patients for timely diagnosis and management.
This CPD activity is presented by Prof Pathmanathan and supported by an educational grant from Astra Zeneca.